Clinical Scorecard: Association of Complement-Producing Cancer-Associated Fibroblasts with Improved Outcomes in Pancreatic Cancer: Insights from Single-Cell Multiomics
At a Glance
Category
Detail
Condition
Key Mechanisms
Heterogeneous cancer-associated fibroblast (CAF) populations with dual protumour and antitumour roles.
Target Population
Care Setting
Key Highlights
Identification of complement-secreting CAFs (csCAFs) as a subtype.
Higher composition of csCAFs correlates with longer overall survival and recurrence-free survival.
Distinct CAF subtypes exhibit varying distributions in primary and metastatic sites.
Guideline-Based Recommendations
Diagnosis
Utilize single-cell RNA sequencing to characterize CAF subtypes in PDAC.
Management
Consider strategies for reprogramming tumour-promoting CAFs.
Monitoring & Follow-up
Assess the composition of CAF subtypes as a potential biomarker.
Risks
CAFs may contribute to therapeutic resistance.
Patient & Prescribing Data
Patients diagnosed with pancreatic ductal adenocarcinoma.
Reprogramming of iCAFs into csCAFs may offer a novel therapeutic approach.
Clinical Best Practices
Employ multiomics approaches to gain insights into CAF heterogeneity.
by Kai Chen, Yongsu Ma, Liling Huang, Pengfei Wu, Heng-Chung Kung, Bohan Yang, Jixin Zhang, Robert A Anders, Jacquelyn W Zimmerman, Qingfeng Zhu, Xiaodong Tian, Jin He, Yinmo Yang
